Skip to main content

Table 1 Clinical and tumor characteristics in patients enrolled in the BOLERO-2 and SOLAR-1 trials (cohort of PIK3CA-mutated cancers)

From: Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Patient/tumor characteristicEverolimus and exemestane group (N = 485)Placebo and exemestane group (N = 239)Alpelisib and fulvestrant group (N = 169)Placebo and fulvestrant group (N = 172)
Age (years)
 Median62616364
 Range34–9328–9025–8738–92
ECOG Performance Statusa (%)
 0605966.365.7
 1363533.133.7
 22300
 Missing dataNANA0.60.6
Visceral disease (%)56565558.1
Metastatic site (%)
 Lung293333.739.5
 Liver33302931.4
 Bone7677NANA
No. of metastatic sites (%)
 0–1322937.330.2
 2313434.334.9
 ≥ 3363728.434.3
Previous chemotherapy (%)
 Neoadjuvant or adjuvant only444059.862.2
 Treatment of metastatic disease (with or without neoadjuvant or adjuvant therapy)262600.6
Previous CDK 4/6 inhibitorsb (%)005.36.4
  1. aECOG Performance Status: Eastern Cooperative Oncology Group Performance Status
  2. bCDK 4/6 : Cyclin-Dependent Kinase 4/6